DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Dr. Bernhard Sixt Edinburgh Molecular Imaging appoints as new Chief Executive Officer

TeamBest companies to acquire ABT Molecular Imaging, launch Best ABT Bringing greater expertise to smaller cyclotron technology

Missouri reactor becomes sole US domestic source of I-131 A vital radioisotope in the fight against thyroid cancer and hyperthyroidism

Zionexa partners with Columbia PET Center on development of EstroTep Identifies estrogen receptor status to diagnose metastatic breast cancer

Cardinal Health to distribute IRE ELiT's 68-Ga generators Aiming to alleviate access shortages with Galli Eo generators

Canada to build medical isotope research and development center Will act as a regional source for isotopes, including Tc-99m

SNMMI warns providers to prep for expected shortage of Mo-99 Due to shutdowns of two reactors

RefleXion demonstrates BgRT PET system at ASTRO Treat all stages of cancer, including metastatic

GE to provide training to at least 140 Kenyan radiographers Partnering with Society of Radiography in Kenya

Adel Abdullah and Aaron Hargrave Positron appoints president and vice president

James Allison, Padmanee Sharma and Ramy Ibrahim

ImaginAb appoints new members to scientific advisory board
July 09, 2018
LOS ANGELES, July 9, 2018 /PRNewswire/ -- ImaginAb Inc., an immuno-oncology imaging company, today announced the appointment of James Allison, Padmanee Sharma and Ramy Ibrahim to its Scientific Advisory Board (SAB) comprised of foremost global key opinion leaders in the development of anticancer therapies.

"We are excited to welcome Jim, Pam and Ramy to our Scientific Advisory Board," said Martyn Coombs, CEO of ImaginAb. "Jim's original work was the basis for the whole immuno-oncology field, and Jim, Pam and Ramy are right at the center of the exciting and rapid developments in immuno-oncology."

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



These additions build on the recent appointments of Antoni Ribas, Dan Von Hoff and David Mankoff. The SAB will work closely with ImaginAb's management team to advance the development of ImaginAb's CD8 T Cell ImmunoPET, an imaging agent that has the potential to expedite the development of next-generation therapeutics.

"I look forward to being a part of ImaginAb's SAB," said Dr. Allison. "ImaginAb's plan, which is to visualize T cells directly in patients in order to determine whether patients will respond to immune checkpoint therapy, will be an important step forward for biomarker development in the field of cancer immunotherapy."

"I'm excited to work with the ImaginAb team as they develop novel strategies to image the immune response in patients," said Dr. Sharma. "These types of advances will help us to improve patient selection and development of immunotherapies."

"I look forward to joining ImaginAb's SAB as their platform is very aligned with the Parker Institute's mission to improve the quality of life of cancer patients undergoing immunotherapy," said Dr. Ibrahim. "Data from their Phase 1 study is very encouraging and using a non-invasive technology to replace the need of biopsies holds great promise for patients."

James Allison: Dr. James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Immunotherapy, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
  Pages: 1 - 2 - 3 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED